Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: human c1-esterase inhibitor, sutimlimab | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,818 | 0.82 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 13093
Sealed predictions
- C1S in dopamine neurons, braak-0.47 (p 0.197) → +0.41 (p 0.276)receipt 13100
Swarm cases
receipt 13100: C1S in dopamine neurons, braak
- power
- full sample -0.14 (p 0.579, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.820, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.351, n 18). could be the mix.
- skeptic
- leave-one-out range -0.25 to -0.01, sign flips 0; without severely affected donors -0.14 (p 0.579, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for C1S in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts